Characterization of 7- and 19-month-old Tg2576 mice using multimodal in vivo imaging: Limitations as a translatable model of Alzheimer's disease

Neurobiology of Aging

Volumn 33, Issue 5, 2012, Pages 933-944

  Luo, Feng ^a   Rustay, Nathan R ^a   Ebert, Ulrich ^b   Hradil, Vincent P ^a   Cole, Todd B ^a   Llano, Daniel A ^a   Mudd, Sarah R ^c   Zhang, Yumin ^a   Fox, Gerard B ^a   Day, Mark ^a  

^a ABBOTT LABORATORIES   (United States)

^b ABBOTT GMBH AND CO KG   (Germany)

^c UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

Alzheimer's disease; APP; Biomarker; Cerebral metabolism; FDG PET; Functional MRI; Hypermetabolism; Hypometabolism; Proton MRS; Transgenic mice

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

AGE; ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL COMPLIANCE; BRAIN BLOOD VOLUME; BRAIN METABOLISM; COGNITIVE DEFECT; CONTROLLED STUDY; FEMALE; FUNCTIONAL MAGNETIC RESONANCE IMAGING; GLUCOSE METABOLISM; HYPERCAPNIA; HYPERMETABOLISM; MOUSE; NEUROIMAGING; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; TRANSGENIC MOUSE;

AGE FACTORS; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN PRECURSOR; ANIMALS; BLOOD GLUCOSE; DISEASE MODELS, ANIMAL; ENERGY METABOLISM; FEMALE; HUMANS; MICE; MICE, TRANSGENIC; NEUROIMAGING; POSITRON-EMISSION TOMOGRAPHY; REPRODUCIBILITY OF RESULTS;

EID: 84858332587     PISSN: 01974580     EISSN: 15581497     Source Type: Journal    
DOI: 10.1016/j.neurobiolaging.2010.08.005     Document Type: Article

References (91)

1. Alexander G.E., Chen K., Pietrini P., Rapoport S.I., Reiman E.M. Longitudinal PET evaluation of cerebral metabolic decline in dementia: a potential outcome measure in Alzheimer's disease treatment studies. Am. J. Psychiatry 2002, 159:738-745.
2. Alsop D.C., Casement M., de Bazelaire C., Fong T., Press D.Z. Hippocampal hyperperfusion in Alzheimer's disease. Neuroimage 2008, 42:1267-1274.
3. Atamna H., Frey W.H. Mechanisms of mitochondrial dysfunction and energy deficiency in Alzheimer's disease. Mitochondrion 2007, 7:297-310.
4. Bhatia R., Lin H., Lal R. Fresh and globular amyloid beta protein (1-42) induces rapid cellular degeneration: evidence for AbetaP channel-mediated cellular toxicity. FASEB J 2000, 14:1233-1243.
5. Boellaard R., van Lingen A., Lammertsma A.A. Experimental and clinical evaluation of iterative reconstruction (OSEM) in dynamic PET: quantitative characteristics and effects on kinetic modeling. J. Nucl. Med 2001, 42:808-817.
6. Burdett N.G., Menon D.K., Carpenter T.A., Jones J.G., Hall L.D. Visualisation of changes in regional cerebral blood flow (rCBF) produced by ketamine using long TE gradient-echo sequences: preliminary results. Magn. Reson. Imaging 1995, 13:549-553.
7. Callahan M.J., Lipinski W.J., Bian F., Durham R.A., Pack A., Walker L.C. Augmented senile plaque load in aged female beta-amyloid precursor protein-transgenic mice. Am. J. Pathol 2001, 158:1173-1177.
8. Chatziioannou A.F., Cherry S.R., Shao Y., Silverman R.W., Meadors K., Farquhar T.H., Pedarsani M., Phelps M.E. Performance evaluation of microPET: a high-resolution lutetium oxyorthosilicate PET scanner for animal imaging. J. Nucl. Med 1999, 40:1164-1175.
9. Clausen T., Van Hardeveld C., Everts M.E. Significance of cation transport in control of energy metabolism and thermogenesis. Physiol. Res 1991, 71:733-774.
10. Constantinescu C.C., Mukherjee J. Performance evaluation of an Inveon PET preclinical scanner. Phys. Med. Biol 2009, 54:2885-2899.
11. Cox R.W. AFNI: software for analysis and visualization of functional magnetic resonance neuroimages. Comput. Biomed. Res 1996, 29:162-173.
12. Day M., Balci F., Wan H.I., Fox G.B., Rutkowski J.L., Feuerstein G. Cognitive endpoints as disease biomarkers: optimizing the congruency of preclinical models to the clinic. Curr. Opin. Investig. Drugs 2008, 9:696-706.
13. de Leon M.J., Convit A., Wolf O.T., Tarshish C.Y., DeSanti S., Rusinek H., Tsui W., Kandil E., Scherer A.J., Roche A., Imossi A., Thorn E., Bobinski M., Caraos C., Lesbre P., Schlyer D., Poirier J., Reisberg B., Fowler J. Prediction of cognitive decline in normal elderly subjects with 2-[(18)F]fluoro-2-deoxy-d-glucose/poitron-emission tomography (FDG/PET). Proc. Natl. Acad. Sci. U. S. A. 2001, 98:10966-10971.
14. Dedeoglu A., Choi J.K., Cormier K., Kowall N.W., Jenkins B.G. Magnetic resonance spectroscopic analysis of Alzheimer's disease mouse brain that express mutant human APP shows altered neurochemical profile. Brain Res 2004, 1012:60-65.
15. Dickerson B.C., Salat D.H., Greve D.N., Chua E.F., Rand-Giovannetti E., Rentz D.M., Bertram L., Mullin K., Tanzi R.E., Blacker D., Albert M.S., Sperling R.A. Increased hippocampal activation in mild cognitive impairment compared to normal aging and AD. Neurology 2005, 65:404-411.
16. Dickerson B.C., Sperling R.A. Neuroimaging biomarkers for clinical trials of disease-modifying therapies in Alzheimer's disease. NeuroRx 2005, 2:348-360.
17. Eidelberg D., Dhawan V., Moeller J.R., Sidtis J.J., Ginos J.Z., Strother S.C., Cederbaum J., Greene P., Fahn S., Powers J.M. The metabolic landscape of cortico-basal ganglionic degeneration: regional asymmetries studied with positron emission tomography. J. Neurol. Neurosurg. Psychiatry 1991, 54:856-862.
18. Etcheberrigaray R., Tan M., Dewachter I., Kuiperi C., Van der Auwera I., Wera S., Qiao L., Bank B., Nelson T.J., Kozikowski A.P., Van Leuven F., Alkon D.L. Therapeutic effects of PKC activators in Alzheimer's disease transgenic mice. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:11141-11146.
19. Fox N.C., Black R.S., Gilman S., Rossor M.N., Griffith S.G., Jenkins L., Koller M. Effects of Abeta immunization (AN1792) on MRI measures of cerebral volume in Alzheimer disease. Neurology 2005, 64:1563-1572.
20. Gabriel M., Sparenborg S.P., Stolar N. Hippocampal control of cingulate cortical and anterior thalamic information processing during learning in rabbits. Exp. Brain Res 1987, 67:131-152.
21. Graham G.D., Zhong J., Petroff O.A., Constable R.T., Prichard J.W., Gore J.C. BOLD MRI monitoring of changes in cerebral perfusion induced by acetazolamide and hypercarbia in the rat. Magn. Reson. Med 1994, 31:557-560.
22. Greene R. Circuit analysis of NMDAR hypofunction in the hippocampus, in vitro, and psychosis of schizophrenia. Hippocampus 2001, 11:569-577.
23. Grunder G. "Absolute" or "relative": choosing the right outcome measure in neuroimaging. Neuroimage 2009, 45:258-259.
24. Gunduz-Bruce H. The acute effects of NMDA antagonism: from the rodent to the human brain. Brain Res. Rev 2009, 60:279-286.
25. Haier R.J., Head K., Head E., Lott I.T. Neuroimaging of individuals with Down's syndrome at-risk for dementia: evidence for possible compensatory events. Neuroimage 2008, 39:1324-1332.
26. Hsiao K. Transgenic mice expressing Alzheimer amyloid precursor proteins. Exp. Gerontol 1998, 33:883-889.
27. Hsiao K., Chapman P., Nilsen S., Eckman C., Harigaya Y., Younkin S., Yang F., Cole G. Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science 1996, 274:99-102.
28. Hudson H.M., Larkin R.S. Accelerated image reconstruction using ordered subsets of projection data. IEEE Trans. Med. Imaging 1994, 13:601-609.
29. Inui A. Transgenic study of energy homeostasis equation: implications and confounding influences. FASEB J 2000, 14:2158-2170.
30. Irizarry M.C., McNamara M., Fedorchak K., Hsiao K., Hyman B.T. APPSw transgenic mice develop age-related A beta deposits and neuropil abnormalities, but no neuronal loss in CA1. J. Neuropathol. Exp. Neurol 1997, 56:965-973.
31. Jack C.R., Slomkowski M., Gracon S., Hoover T.M., Felmlee J.P., Stewart K., Xu Y., Shiung M., O'Brien P.C., Cha R., Knopman D., Petersen R.C. MRI as a biomarker of disease progression in a therapeutic trial of milameline for AD. Neurology 2003, 60:253-260.
32. Jacobsen J.S., Wu C.C., Redwine J.M., Comery T.A., Arias R., Bowlby M., Martone R., Morrison J.H., Pangalos M.N., Reinhart P.H., Bloom F.E. Early-onset behavioral and synaptic deficits in a mouse model of Alzheimer's disease. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:5161-5166.
33. Jagust W. Positron emission tomography and magnetic resonance imaging in the diagnosis and prediction of dementia. Alzheimers Dement 2006, 2:36-42.
34. Jagust W.J., Eberling J.L. MRI, CT, SPECT, PET: their use in diagnosing dementia. Geriatrics 1991, 46:28-35.
35. Kawarabayashi T., Younkin L.H., Saido T.C., Shoji M., Ashe K.H., Younkin S.G. Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J. Neurosci 2001, 21:372-381.
36. Kayed R., Sokolov Y., Edmonds B., McIntire T.M., Milton S.C., Hall J.E., Glabe C.G. Permeabilization of lipid bilayers is a common conformation-dependent activity of soluble amyloid oligomers in protein misfolding diseases. J. Biol. Chem 2004, 279:46363-46366.
37. King J.A., Garelick T.S., Brevard M.E., Chen W., Messenger T.L., Duong T.Q., Ferris C.F. Procedure for minimizing stress for fMRI studies in conscious rats. J. Neurosci. Methods 2005, 148:154-160.
38. Klunk W.E., Lopresti B.J., Ikonomovic M.D., Lefterov I.M., Koldamova R.P., Abrahamson E.E., Debnath M.L., Holt D.P., Huang G.F., Shao L., DeKosky S.T., Price J.C., Mathis C.A. Binding of the positron emission tomography tracer Pittsburgh compound B reflects the amount of amyloid-beta in Alzheimer's disease brain but not in transgenic mouse brain. J. Neurosci 2005, 25:10598-10606.
39. Kuntner C., Kesner A.L., Bauer M., Kremslehner R., Wanek T., Mandler M., Karch R., Stanek J., Wolf T., Muller M., Langer O. Limitations of small animal PET imaging with [18F]FDDNP and FDG for quantitative studies in a transgenic mouse model of Alzheimer's disease. Mol. Imaging Biol 2009, 11:236-240.
40. Lanz T.A., Carter D.B., Merchant K.M. Dendritic spine loss in the hippocampus of young PDAPP and Tg2576 mice and its prevention by the ApoE2 genotype. Neurobiol. Dis 2003, 13:246-253.
41. Leahy R.M., Qi J. Statistical approaches in quantitative positron emission tomography. Stat. Comput 2000, 10:147-165.
42. Lengyel Z., Balogh E., Emri M., Szikszai E., Kollar J., Sikula J., Esik O., Tron L., Olah E. Pattern of increased cerebral FDG uptake in Down syndrome patients. Pediatr. Neurol 2006, 34:270-275.
43. Leopold D.A., Plettenberg H.K., Logothetis N.K. Visual processing in the ketamine-anesthetized monkey. Optokinetic and blood oxygenation level-dependent responses. Exp. Brain Res 2002, 143:359-372.
44. Littlewood C.L., Cash D., Dixon A.L., Dix S.L., White C.T., O'Neill M.J., Tricklebank M., Williams S.C. Using the BOLD MR signal to differentiate the stereoisomers of ketamine in the rat. Neuroimage 2006, 32:1733-1746.
45. Lowry J.P., Fillenz M. Real-time monitoring of brain energy metabolism in vivo using microelectrochemical sensors: the effects of anesthesia. Bioelectrochemistry 2001, 54:39-47.
46. Luo F., Seifert T.R., Edalji R., Loebbert R.W., Hradil V.P., Harlan J., Schmidt M., Nimmrich V., Cox B.F., Fox G.B. Non-invasive characterization of beta-amyloid(1-40) vasoactivity by functional magnetic resonance imaging in mice. Neuroscience 2008, 155:263-269.
47. Luo F., Wu G., Li Z., Li S.J. Characterization of effects of mean arterial blood pressure induced by cocaine and cocaine methiodide on BOLD signals in rat brain. Magn. Reson. Med 2003, 49:264-270.
48. Luo F., Xi Z.X., Wu G., Liu C., Gardner E.L., Li S.J. Attenuation of brain response to heroin correlates with the reinstatement of heroin-seeking in rats by fMRI. Neuroimage 2004, 22:1328-1335.
49. Mandeville J.B., Marota J.J., Kosofsky B.E., Keltner J.R., Weissleder R., Rosen B.R., Weisskoff R.M. Dynamic functional imaging of relative cerebral blood volume during rat forepaw stimulation. Magn. Reson. Med 1998, 39:615-624.
50. Mantani T., Okamoto Y., Shirao N., Okada G., Yamawaki S. Reduced activation of posterior cingulate cortex during imagery in subjects with high degrees of alexithymia: a functional magnetic resonance imaging study. Biol. Psychiatry 2005, 57:982-990.
51. Marjanska M., Curran G.L., Wengenack T.M., Henry P.G., Bliss R.L., Poduslo J.F., Jack C.R., Ugurbil K., Garwood M. Monitoring disease progression in transgenic mouse models of Alzheimer's disease with proton magnetic resonance spectroscopy. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:11906-11910.
52. Matsumura A., Mizokawa S., Tanaka M., Wada Y., Nozaki S., Nakamura F., Shiomi S., Ochi H., Watanabe Y. Assessment of microPET performance in analyzing the rat brain under different types of anesthesia: comparison between quantitative data obtained with microPET and ex vivo autoradiography. Neuroimage 2003, 20:2040-2050.
53. McGowan E., Eriksen J., Hutton M. A decade of modeling Alzheimer's disease in transgenic mice. Trends Genet 2006, 22:281-289.
54. Mega M.S., Chen S.S., Thompson P.M., Woods R.P., Karaca T.J., Tiwari A., Vinters H.V., Small G.W., Toga A.W. Mapping histology to metabolism: coregistration of stained whole-brain sections to premortem PET in Alzheimer's disease. Neuroimage 1997, 5:147-153.
55. Miller G. Alzheimer's biomarker initiative hits its stride. Science 2009, 326:386-389.
56. Mirrione M.M., Schiffer W.K., Fowler J.S., Alexoff D.L., Dewey S.L., Tsirka S.E. A novel approach for imaging brain-behavior relationships in mice reveals unexpected metabolic patterns during seizures in the absence of tissue plasminogen activator. Neuroimage 2007, 38:34-42.
57. Moe B., Angelier F., Bech C., Chastel O. Is basal metabolic rate influenced by age in a long-lived seabird, the snow petrel?. J. Exp. Biol 2007, 210:3407-3414.
58. Morgan D., Gordon M.N. Amyloid, hyperactivity, and metabolism: theoretical comment on Vloeberghs et al. Behav. Neurosci 2008, 122:730-732.
59. Mosconi L. Brain glucose metabolism in the early and specific diagnosis of Alzheimer's disease. FDG-PET studies in MCI and AD. Eur. J. Nucl. Med. Mol. Imaging 2005, 32:486-510.
60. Mueggler T., Sturchler-Pierrat C., Baumann D., Rausch M., Staufenbiel M., Rudin M. Compromised hemodynamic response in amyloid precursor protein transgenic mice. J. Neurosci 2002, 22:7218-7224.
61. Myers R., Hume S. Small animal PET. Eur. Neuropsychopharmacol 2002, 12:545-555.
62. Nicolakakis N., Aboulkassim T., Ongali B., Lecrux C., Fernandes P., Rosa-Neto P., Tong X.K., Hamel E. Complete rescue of cerebrovascular function in aged Alzheimer's disease transgenic mice by antioxidants and pioglitazone, a peroxisome proliferator-activated receptor gamma agonist. J. Neurosci 2008, 28:9287-9296.
63. Niwa K., Kazama K., Younkin S.G., Carlson G.A., Iadecola C. Alterations in cerebral blood flow and glucose utilization in mice overexpressing the amyloid precursor protein. Neurobiol. Dis 2002, 9:61-68.
64. Norfray J.F., Provenzale J.M. Alzheimer's disease: neuropathologic findings and recent advances in imaging. AJR Am. J. Roentgenol 2004, 182:3-13.
65. Ohno M., Sametsky E.A., Younkin L.H., Oakley H., Younkin S.G., Citron M., Vassar R., Disterhoft J.F. BACE1 deficiency rescues memory deficits and cholinergic dysfunction in a mouse model of Alzheimer's disease. Neuron 2004, 41:27-33.
66. Palop J.J., Chin J., Roberson E.D., Wang J., Thwin M.T., Bien-Ly N., Yoo J., Ho K.O., Yu G.Q., Kreitzer A., Finkbeiner S., Noebels J.L., Mucke L. Aberrant excitatory neuronal activity and compensatory remodeling of inhibitory hippocampal circuits in mouse models of Alzheimer's disease. Neuron 2007, 55:697-711.
67. Phelps M.E. Inaugural article: positron emission tomography provides molecular imaging of biological processes. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:9226-9233.
68. PET Physics, Instrumentation, and Scanners 2006, Springer, New York. M.E. Phelps (Ed.).
69. Potkin S.G., Anand R., Fleming K., Alva G., Keator D., Carreon D., Messina J., Wu J.C., Hartman R., Fallon J.H. Brain metabolic and clinical effects of rivastigmine in Alzheimer's disease. Int. J. Neuropsychopharmacol 2001, 4:223-230.
70. Reiman E.M., Chen K., Alexander G.E., Caselli R.J., Bandy D., Osborne D., Saunders A.M., Hardy J. Correlations between apolipoprotein E epsilon4 gene dose and brain-imaging measurements of regional hypometabolism. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:8299-8302.
71. Reiman E.M., Uecker A., Gonzalez-Lima F., Minear D., Chen K., Callaway N.L., Berndt J.D., Games D. Tracking Alzheimer's disease in transgenic mice using fluorodeoxyglucose autoradiography. Neuroreport 2000, 11:987-991.
72. Roberson E.D., Mucke L. 100 years and counting: prospects for defeating Alzheimer's disease. Science 2006, 314:781-784.
73. Ronning B., Jensen H., Moe B., Bech C. Basal metabolic rate: heritability and genetic correlations with morphological traits in the zebra finch. J. Evol. Biol 2007, 20:1815-1822.
74. Spires T.L., Hyman B.T. Transgenic models of Alzheimer's disease: learning from animals. NeuroRx 2005, 2:423-437.
75. Stein E.A. fMRI: a new tool for the in vivo localization of drug actions in the brain. J. Anal. Toxicol 2001, 25:419-424.
76. Tai Y.C., Chatziioannou A.F., Yang Y., Silverman R.W., Meadors K., Siegel S., Newport D.F., Stickel J.R., Cherry S.R. MicroPET. II: design, development and initial performance of an improved microPET scanner for small-animal imaging. Phys. Med. Biol 2003, 48:1519-1537.
77. Teipel S.J., Drzezga A., Bartenstein P., Moller H.J., Schwaiger M., Hampel H. Effects of donepezil on cortical metabolic response to activation during (18)FDG-PET in Alzheimer's disease: a double-blind cross-over trial. Psychopharmacology 2006, 187:86-94.
78. Thal L.J., Kantarci K., Reiman E.M., Klunk W.E., Weiner M.W., Zetterberg H., Galasko D., Pratico D., Griffin S., Schenk D., Siemers E. The role of biomarkers in clinical trials for Alzheimer disease. Alzheimer Dis. Assoc. Disord 2006, 20:6-15.
79. Thie J.A. Understanding the standardized uptake value, its methods, and implications for usage. J. Nucl. Med 2004, 45:1431-1434.
80. Toyama H., Ichise M., Liow J.S., Modell K.J., Vines D.C., Esaki T., Cook M., Seidel J., Sokoloff L., Green M.V., Innis R.B. Absolute quantification of regional cerebral glucose utilization in mice by 18F-FDG small animal PET scanning and 2-14C-DG autoradiography. J. Nucl. Med 2004, 45:1398-1405.
81. Ulugol A., Dost T., Dokmeci D., Akpolat M., Karadag C.H., Dokmeci I. Involvement of NMDA receptors and nitric oxide in the thermoregulatory effect of morphine in mice. J. Neural Transm 2000, 107:515-521.
82. Valla J., Gonzalez-Lima F., Reiman E.M. FDG autoradiography reveals developmental and pathological effects of mutant amyloid in PDAPP transgenic mice. Int. J. Dev. Neurosci 2008, 26:253-258.
83. Van der Linden A., Van Camp N., Ramos-Cabrer P., Hoehn M. Current status of functional MRI on small animals: application to physiology, pathophysiology, and cognition. NMR Biomed 2007, 20:522-545.
84. Vann S.D., Brown M.W., Aggleton J.P. Fos expression in the rostral thalamic nuclei and associated cortical regions in response to different spatial memory tests. Neuroscience 2000, 101:983-991.
85. Visser E.P., Disselhorst J.A., Brom M., Laverman P., Gotthardt M., Oyen W.J., Boerman O.C. Spatial resolution and sensitivity of the Inveon small-animal PET scanner. J. Nucl. Med 2009, 50:139-147.
86. Vloeberghs E., Van Dam D., Franck F., Serroyen J., Geert M., Staufenbiel M., De Deyn P.P. Altered ingestive behavior, weight changes, and intact olfactory sense in an APP overexpression model. Behav. Neurosci 2008, 122:491-497.
87. Vorstrup S., Henriksen L., Paulson O.B. Effect of acetazolamide on cerebral blood flow and cerebral metabolic rate for oxygen. J. Clin. Invest 1984, 74:1634-1639.
88. Weber R., Ramos-Cabrer P., Wiedermann D., van Camp N., Hoehn M. A fully noninvasive and robust experimental protocol for longitudinal fMRI studies in the rat. Neuroimage 2006, 29:1303-1310.
89. Werner C., Kochs E., Rau M., Blanc I., Am Esch J.S. Dose-dependent blood flow velocity changes in the Basal cerebral arteries following low-dose ketamine. J. Neurosurg. Anesthesiol 1990, 2:86-91.
90. Westerman M.A., Cooper-Blacketer D., Mariash A., Kotilinek L., Kawarabayashi T., Younkin L.H., Carlson G.A., Younkin S.G., Ashe K.H. The relationship between Abeta and memory in the Tg2576 mouse model of Alzheimer's disease. J. Neurosci 2002, 22:1858-1867.
91. Yang Y., Tai Y.C., Siegel S., Newport D.F., Bai B., Li Q., Leahy R.M., Cherry S.R. Optimization and performance evaluation of the microPET II scanner for in vivo small-animal imaging. Phys. Med. Biol 2004, 49:2527-2545.